Grail’s Galleri Blood Test Falls Short in Large Cancer-Screening Study, Shares Sink 50%

Frank Vinluan / medcitynews - Despite missing statistical significance, Grail said the observation of trending improvement suggests potential for better results with more time, so the company is extending follow up by up to a year. More detailed trial results will be submitted for pre…

AI Summary: Grail’s multi‑cancer Galleri blood screen failed to meet the primary endpoint in a large UK trial, undermining claims of near-term population screening utility and prompting a sharp market reaction. Researchers noted signals that merit further study, but the study outcome raises fresh doubts about broad clinical deployment and reimbursement prospects.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Major study finds GRAIL multi‑cancer blood test did not detect cancers earlier / 3 months

Previously unknown virus found inside gut bacteria linked to colorectal cancer / 3 months

Liquid biopsy may speed childhood Burkitt lymphoma diagnosis in Africa / 2 months

FDA clears wearable electric-field therapy for pancreatic cancer patients / 3 months

Microplastics detected in most prostate cancer tumors, study finds / 3 months

Researchers grow liver tissue in patients' bodies; study now under scrutiny / 6 wks

Ultra‑sensitive ctDNA blood test could personalize breast cancer care for older women / 2 months